<DOC>
	<DOCNO>NCT00176904</DOCNO>
	<brief_summary>The purpose study determine safety engraftment donor hematopoietic cell use condition regimen patient undergo hematopoietic ( blood forming ) cell transplant inherit metabolic storage disease .</brief_summary>
	<brief_title>Stem Cell Transplant Inborn Errors Metabolism</brief_title>
	<detailed_description>Prior transplantation , subject receive Busulfan intravenously ( IV ) via Hickman line four time daily 4 day , Cyclophosphamide intravenously via Hickman line day 4 day , Anti-Thymocyte Globulin ( ATG ) intravenously ( IV ) via Hickman line twice daily three day transplant . These three drug give subject help new marrow `` take '' grow . On day transplantation , donor 's hematopoietic cell transfuse via central venous catheter . After hematopoietic cell transplant , subject receive two drug , cyclosporin either methylprednisolone Mycophenolate Mofetil ( MMF ) . Cyclosporin methylprednisolone MMF give help prevent complication graft-versus-host disease decrease chance new donor cell reject .</detailed_description>
	<mesh_term>Gaucher Disease</mesh_term>
	<mesh_term>Metabolism , Inborn Errors</mesh_term>
	<mesh_term>Adrenoleukodystrophy</mesh_term>
	<mesh_term>Pick Disease Brain</mesh_term>
	<mesh_term>Aphasia , Primary Progressive</mesh_term>
	<mesh_term>Frontotemporal Dementia</mesh_term>
	<mesh_term>Gangliosidoses</mesh_term>
	<mesh_term>Tay-Sachs Disease</mesh_term>
	<mesh_term>Wolman Disease</mesh_term>
	<mesh_term>Leukodystrophy , Metachromatic</mesh_term>
	<mesh_term>Niemann-Pick Diseases</mesh_term>
	<mesh_term>Niemann-Pick Disease , Type A</mesh_term>
	<mesh_term>Niemann-Pick Disease , Type C</mesh_term>
	<mesh_term>Neuronal Ceroid-Lipofuscinoses</mesh_term>
	<mesh_term>Leukodystrophy , Globoid Cell</mesh_term>
	<mesh_term>Sandhoff Disease</mesh_term>
	<mesh_term>Fucosidosis</mesh_term>
	<mesh_term>Gangliosidosis , GM1</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Patients adrenoleukodystrophy , metachromatic leukodystrophy , globoid cell leukodystrophy , Gaucher 's disease , Fucosidosis , Wolman disease , NiemannPick disease Batten disease ( CLN3 ) human leukocyte antigen ( HLA ) identical haplotype mismatch ( 13 antigen ) relate marrow , umbilical cord blood donor . One two umbilical cord blood ( UCB ) unit may use . Patients GM1 gangliosidosis , Tay Sachs disease Sandhoff disease HLAidentical 1 antigen mismatch related unrelated donor , suitably match umbilical cord blood unit ( ) . One two UCB unit may use . Patients adrenoleukodystrophy must magnetic resonance imaging ( MRI ) finding , neurological neuropsychometric function consistent diagnosis , boys parietaloccipital dysmyelination performance intelligence quotient ( IQ ) ≥80 . In case , performance IQ ≥80 , protocol committee may recommend transplant patient 's clinical condition neuropsychometric status deem acceptable base upon consideration factor age onset cerebral disease , magnitude change performance IQ neurologic deficit . Patients arylsulfatase A deficiency ( Metachromatic Leukodystrophy ) must either presymptomatic late infantile , juvenile adult form disease must acceptable neurological neuropsychometric function . Patients galactocerebrosidase deficiency ( Globoid Cell Leukodystrophy ) must acceptable neurological neuropsychometric function . Patients acid lipase deficiency ( Wolman disease ) must liver biopsy document evidence hepatic cirrhosis , acceptable neurological neuropsychometric function . Patients fucosidase deficiency ( Fucosidosis ) must acceptable neurological neuropsychometric function . Patients glucocerebrosidase deficiency ( Gaucher 's Disease ) must acceptable neurologic neuropsychometric function . Patients Batten 's disease ( CLN3 ) must acceptable Neurological neuropsychometric function . Absence major organ dysfunction . Organ evaluation result follow : Cardiac : ejection fraction &gt; 30 % Renal : serum creatinine &lt; 2x normal creatinine clearance 60 mL/min . Hepatic : total bilirubin &lt; 2x normal Aspartate aminotransferase ( AST ) &lt; 2x normal Signed consent . Patients symptomatic late infantile form metachromatic leukodystrophy . Patients symptomatic infantile globoid leukodystrophy . Note : Patients Hurler syndrome , mucopolysaccharidosis ( MPS ) VI , Mannosidosis disease longer eligible protocol , transplant protocol MT 9907 ( NCT00176917 Hematopoietic Cell Transplantation Hurler Syndrome , Maroteaux Lamy Syndrome ( MPS VI ) , Alpha Mannosidase Deficiency ( Mannosidosis ) ) . Pregnancy Evidence human immunodeficiency virus ( HIV ) infection know HIV positive serology Patients parent psychologically incapable undergo bone marrow transplant ( BMT ) associate strict isolation document history medical noncompliance . Patients ≥ 50 kg may risk cell dos goal ≥ 10 x 10^6 CD34 cells/kg therefore eligible receive unrelated peripheral blood stem cell ( PBSCs )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Inborn error</keyword>
	<keyword>Storage disease</keyword>
	<keyword>error metabolism</keyword>
	<keyword>stem cell transplant</keyword>
</DOC>